|Year : 2020 | Volume
| Issue : 2 | Page : 82-85
Fluorodeoxyglucose-avid thyroid incidentaloma
Deepanjan Mitra1, Sujoy Ghosh2
1 Department of Nuclear Medicine, AMRI Hospitals, Kolkata, West Bengal, India
2 Department of Endocrinology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India
|Date of Submission||12-Dec-2019|
|Date of Acceptance||18-Jan-2020|
|Date of Web Publication||17-Jul-2020|
Prof. Sujoy Ghosh
Department of Endocrinology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal
Source of Support: None, Conflict of Interest: None
Positron emission tomography–computed tomography (PET-CT) has become a standard investigation oncology workup.18F-fluorodeoxyglucose (18F-FDG) is the main radiopharmaceuticals for most of the studies. Since malignant cells overexpress glucose transporter receptors, they internalize FDG, and FDG undergoes the first rate-limiting step of glycolysis to form FDG-6-phosphate. In a whole-body PET-CT study, a lot of incidental findings are noticed and often bear significant clinical relevance. A normal thyroid gland does not show any demonstrable FDG uptake. However, sometimes, a normal-looking thyroid gland shows up increased FDG uptake in a diffuse manner in both lobes without any obvious focal FDG-avid lesion. This is attributed to autoimmune lymphocytic thyroid diseases and hypothyroidism. A hyperthyroid gland may appear diffusely enlarged with intense FDG uptake throughout the gland suggesting the hyperfunctioning of its follicular cells. However, any focal FDG uptake in either lobe of the thyroid needs an evaluation, particularly if there is any hypodense nodule on corresponding CT study. It is observed that FDG-avid thyroid nodules can harbor malignancy in almost 33% of cases. Hence, any FDG-avid incidentaloma needs an image-guided fine-needle aspiration cytology to rule out occult malignancy.
Keywords: Fluorodeoxyglucose, incidentaloma, positron emission tomography–computed tomography, thyroid
|How to cite this article:|
Mitra D, Ghosh S. Fluorodeoxyglucose-avid thyroid incidentaloma. Thyroid Res Pract 2020;17:82-5
| Introduction|| |
Positron emission tomography–computed tomography (PET-CT) has become a standard investigative modality in recent oncology workup. The major workhorse for PET-CT study is18 F-fluorodeoxyglucose (18 F-FDG). Malignant cells overexpress glucose transporter (GLUT) receptors on their surface and hence internalize18 F-FDG. The FDG undergoes the rate-limiting step of glycolysis and forms FDG-6-phosphate. However, due to the absence of hydroxyl group in the second carbon of native glucose molecule, FDG does not undergo the further steps of glycolysis and gets trapped within the cell. The trapping of FDG is directly proportional to the number of GLUT receptors expressed and rate of glycolysis, which is increased in malignant cells (Warburg effect). This forms the basis of increased amount of FDG uptake by malignant cells compared to normals.
However, FDG is not malignant specific. FDG is often taken up by infective inflammatory cells due to increased glycolytic activity by inflammatory macrophages as well. Hence, careful assessment of FDG uptake is necessary in order to increase the specificity of PET-CT findings.
Many organs normally take up glucose for their metabolism such as brain, lymphoid tissue in Waldeyer's ring, myocardium (often show variable uptake), liver, kidney, and bladder (due to urinary excretion of FDG) and hence show increased uptake of FDG in a PET-CT study.
A normal thyroid gland does not show any demonstrable FDG uptake in a PET-CT study. However, sometimes, a normal-looking thyroid gland shows up increased FDG uptake in a diffuse manner in both lobes without any obvious focal FDG-avid lesion. This is attributed to autoimmune lymphocytic thyroid diseases and hypothyroidism. A hyperthyroid gland may appear diffusely enlarged with intense FDG uptake throughout the gland suggesting the hyperfunctioning of its follicular cells. However, any focal FDG uptake in either lobe of the thyroid needs an evaluation, particularly if there is any hypodense nodule on corresponding CT slides. It is observed that FDG-avid thyroid nodule can harbor malignancy in almost 33% of cases., Hence, any FDG-avid incidentaloma needs an image-guided fine-needle aspiration cytology (FNAC) to rule out occult malignancy.
We present two cases in this context to give an impression.
| Care Reports|| |
A 67-year-old gentleman presented with right hypochondrial pain for 15 days. He had no other symptoms and been otherwise fit. On a screening Ultrasonogram abdomen, a contracted and thickened gallbladder was detected along with a space-occupying lesion in the liver. FNAC of the liver lesion showed features of metastatic disease. A three-phase CT scan of the liver showed thick-walled contracted gallbladder with a lesion in liver parenchyma that raised a possibility of gallbladder malignancy with liver metastasis.
The patient came to our side for an18 F-FDG PET-CT scan. PET-CT was performed as per standard protocol, and a contrast-enhanced CT study was performed along with. The scan demonstrated a thick-walled contracted gallbladder on CT with no evidence of FDG uptake [Figure 1]. There was a hypodense lesion in segment IV of the liver with intense FDG uptake [Figure 2]. Bilateral lung fields showed multiple small nodules. Most of the nodules in the lung did not show any definite FDG uptake (might be due to limited resolution of PET system – small metastatic nodules in the lung often do not show any FDG uptake) except one nodule in apical segment of the lower lobe of the right lung [Figure 3]. Hypodense nodules were seen in both lobes of the thyroid, the larger one measuring 15 mm × 12 mm in size in the right lobe. The right lobe nodule showed intense FDG uptake, whereas the left lobe nodule was FDG nonavid [Figure 4].
|Figure 1: Computed tomography scan shows a thickened gallbladder. The positron emission tomography–computed tomography fusion image shows No obvious fluorodeoxyglucose uptake in the thickened gallbladder|
Click here to view
|Figure 2: The computed tomography scan shows a heterogeneously enhancing lesion in segment IV of the liver. The corresponding positron emission tomography–computed tomography slice shows intense fluorodeoxyglucose uptake in the liver lesion|
Click here to view
|Figure 3: Variably fluorodeoxyglucose-avid lung nodules are seen. Some of the nodules are fluorodeoxyglucose nonavid|
Click here to view
|Figure 4: The nodule in the right lobe of the thyroid is intensely fluorodeoxyglucose avid–subsequent fine-needle aspiration cytology showed papillary thyroid carcinoma|
Click here to view
The impression of an occult thyroid carcinoma was made due to intensely FDG-avid nodule in the right lobe. Due to the absence of any FDG uptake in the nodule in the left lobe, the possibility of malignancy appeared lower. Multiple lung nodules with variable FDG uptake appeared metastatic in nature. The FDG-avid solitary liver lesion was also reported as metastatic lesion, probably from thyroid origin. Due to no definite FDG uptake in thickened gallbladder, there was a suggestion of chronic cholecystitis.
The role of FDG PET in gallbladder carcinoma and cholangiocarcinoma is doubtful. It is observed that both the malignancies may be of less metabolic potential and hence may appear less FDG avid. The liver lesion appeared intensely FDG avid on PET-CT study and thus reduced the possibility of it being a cholangiocarcinoma. If it was metastatic lesion from gall bladder then Gall bladder should have same intense FDG uptake also. Discordant finding between gallbladder and liver lesions was contradictory for it being a metastatic disease from the gallbladder. With an FDG-avid incidentaloma in the right lobe of the thyroid along with multiple lung nodules and an FDG-avid liver lesion, a possibility of occult thyroid malignancy with metastatic lung–liver disease was raised. A USG-guided FNAC of the nodule from the right lobe of the thyroid revealed follicular thyroid carcinoma. A repeat biopsy from the liver lesion revealed this to be a metastatic disease from thyroid carcinoma with follicular thyroid cells.
A 30-year-old female presented with chronic nonproductive cough for the past 2 years. Her initial diagnosis was made as dilated cardiomyopathy which was changed to tuberculosis after seeing miliary mottling on her chest CT study. She was started with antitubercular drugs (ATDs) 1.5 years back. She did not respond to the treatment even after 4 months of her ATD therapy. The diagnosis was changed to sarcoidosis and given steroid therapy with no effect.
Recently, she had undergone a repeat chest CT scan that showed miliary mottling in bilateral lung fields with a nodule of 1.5 cm diameter in the lower lobe of the left lung. There were associated minimal bilateral pleural and pericardial effusions as well. The FNAC of the nodule could not be successful due to the small size of the lesion. Bronchoscopic lavage showed evidence of adenocarcinoma, and hence, she was diagnosed as a case of bronchogenic carcinoma.
She was referred for a PET-CT scan for staging of the disease. The FDG PET-CT scan revealed diffusely increased FDG uptake in bilateral lung fields corresponding to miliary mottling in both parenchyma [Figure 5] and [Figure 6]. No obvious FDG uptake was noted in pleuropericardial effusion. The nodule in the lower lobe of the left lung was also FDG avid [Figure 7]. However, in the whole-body PET-CT image, an FDG-avid hypodense nodule was detected in the left lobe of the thyroid [Figure 8]. In the given clinical context, we raised a possibility of an occult thyroid carcinoma with metastatic lung disease. FNAC of the thyroid nodule showed papillary thyroid carcinoma. The review of the bronchial lavage showed a papillary variety of adenocarcinoma.
|Figure 5: Whole-body positron emission tomography–computed tomography fuse image shows diffuse fluorodeoxyglucose uptake in bilateral lung fields|
Click here to view
|Figure 8: A hypodense nodule detected in the left lobe of the thyroid which shows increased fluorodeoxyglucose uptake in fused positron emission tomography–computed tomography images (mild misregistration of positron emission tomography and computed tomography data noted due to head movement during the scan)|
Click here to view
| Discussion|| |
Thyroid nodular disease is a worldwide clinical problem with prevalence ranging from 20% to 50% of the general population with higher prevalence in currently and previously iodine-deficient areas. However, thyroid cancers are rare, accounting for about 2%–5% of all thyroid nodules.,, The diagnostic evaluation of thyroid nodules includes laboratory tests and thyroid ultrasonography (US). US features are also employed to stratify the risk of malignancy and to select those nodules requiring US-guided FNAC.,18 F-FDG PET is widely used to detect malignancy in many other tumor types, and FDG-avid thyroid nodules found incidentally on FDG-PET scan performed for nonthyroidal disease present a risk of malignancy ranging between 14% and 50% in most studies., The American Thyroid Association recommends performing a “prompt evaluation” by FNAC of all thyroid nodules showing FDG uptake even if in the absence of suspicious US findings. On the other hand, the systematic use of this technique in the presurgical evaluation of thyroid nodules is currently not recommended. This is due to discordant results among studies reporting a sensitivity and specificity of FDG-PET in detecting malignancy ranging from 60% to 100% and 40% to 90%, respectively., These discrepancies seem to be related to the small samples studied and/or to the differences in the inclusion criteria. Most studies reported a low positive predictive value (around 30%) essentially due to a high number of false-positive results represented by benign nodules with FDG uptake. The reported negative predictive value is usually high (80%–100%) essentially due to the small proportion of thyroid cancers among nodules, suggesting that FDG-PET could be useful to avoid unnecessary surgery for benign nodules.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009;324:1029-33.
Kouijzer IJ, Mulders-Manders CM, Bleeker-Rovers CP, Oyen WJ. Fever of unknown origin: The value of FDG-PET/CT. Semin Nucl Med 2018;48:100-7.
Karantanis D, Bogsrud TV, Wiseman GA, Mullan BP, Subramaniam RM, Nathan MA, et al
. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med 2007;48:896-901.
Choi JY, Lee KS, Kim HJ, Shim YM, Kwon OJ, Park K, et al
. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: Clinical significance and improved characterization. J Nucl Med 2006;47:609-15.
Shen B, Huang T, Sun Y, Jin Z, Li XF. Revisit 18F-fluorodeoxyglucose oncology positron emission tomography: Systems molecular imaging of glucose metabolism. Oncotarget 2017;8:43536-42.
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al
. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.
Coleman PM, Babb P, Damiecki P, Grosclaude P, Honjo S, Jones J, et al
. Cancer Survival Trends in England and Wales 1971–1995: Deprivation and NHS Region Series SMPS no. 61, London: Stationery Office; 1999. p. 471-8.
Ruggeri RM, Campennì A, Baldari S, Trimarchi F, Trovato M. What is new on thyroid cancer biomarkers. Biomark Insights 2008;3:237-52.
Campennì A, Giovanella L, Siracusa M, Stipo ME, Alibrandi A, Cucinotta M, et al
. Is malignant nodule topography an additional risk factor for metastatic disease in low-risk differentiated thyroid cancer? Thyroid 2014;24:1607-11.
Giovanella L, Suriano S, Maffioli M, Ceriani L, Spriano G. (99m) Tc-sestamibi scanning in thyroid nodules with nondiagnostic cytology. Head Neck 2010;32:607-11.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al
. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-33.
Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Collins DA, et al
. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun 2007;28:373-81.
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al
. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
Sebastianes FM, Cerci JJ, Zanoni PH, Soares J Jr., Chibana LK, Tomimori EK, et al
. Role of 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 2007;92:4485-8.
Hales NW, Krempl GA, Medina JE. Is there a role for fluorodeoxyglucose positron emission tomography/computed tomography in cytologically indeterminate thyroid nodules? Am J Otolaryngol 2008;29:113-8.
de Geus-Oei LF, Pieters GF, Bonenkamp JJ, Mudde AH, Bleeker-Rovers CP, Corstens FH, et al
. 18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med 2006;47:770-5.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8]